ChemPartner PharmaTech Co., Ltd.

State-of-the-art facility in Watertown, MA, set to open September 10, 2025, offering comprehensive CRO services and seamless collaboration with the Boston biopharma ecosystem SHANGHAI and WATERTOWN, Mass., Aug. 20, 2025 /PRNewswire/ -- ChemPartner, a leading global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), today announced its strategic expansion in the U.S. with the upcoming opening of the ChemPartner Boston Center of Excellence. Located at 480 Arsenal Way in Watertown, MA, the new R&D site will commence operations on September 10, 2025, providing discovery and preclinical services to biopharma clients in North America and beyond. "As demand grows for more localized, agile, and collaborative research partnerships, this expansion reflects our commitment to meeting clients where they are - both scientifically and geographically," said William Woo, Chairman and CEO of ChemPartner. "We're excited to embed ourselves in the Boston life sciences hub, strengthen client partnerships, and deliver more personalized, streamlined support across the drug discovery and development pipeline." ChemPartner's new U.S. site, located in the heart of the Boston biotech corridor, is designed to strengthen collaboration with the region's innovative biotech and pharmaceutical community. Offering biologics discovery, pharmacology, and DMPK services, the site supports both in vitro and in vivo studies from early discovery through IND-enabling stages. As an extension of ChemPartner's global network, it enhances flexibility for North American partners needing onshore capabilities while improving logistics and enabling faster, more seamless coordination across regions. "Our partners face increasing complexity, from bespoke service needs and tighter timelines to evolving regulatory requirements and shipping restrictions," said Yinfei Yin, Managing Director at ChemPartner. "The Boston Center of Excellence will address these challenges head-on while upholding the scientific expertise ChemPartner is known for." The facility spans approximately 12,000 square feet and will open with an experienced scientific team ready to support clients locally and globally. Equipment installation is underway, with initial projects slated to launch this fall. About ChemPartner: ChemPartner US Corporation is the wholly owned subsidiary of ChemPartner Group and offers a broad range of drug discovery, development, and manufacturing services including chemistry and biologics discovery, pharmacology, DMPK, and exploratory toxicology and development and manufacturing CDMO services. Shanghai ChemPartner serves a diverse global client base, with laboratories, business offices, and representatives in the U.S., Europe, China, and Australia. For more information about ChemPartner's U.S. expansion or services, please visit SOURCE ChemPartner WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as reagents from local manufacturers, industry executives and managers said, as they seek to cut costs and delivery times. Western reagent suppliers including U.S.-based Thermo Fisher Scientific and Germany's Merck have profited in the world's second-largest pharmaceutical market from the compounds used in lab tests for analysis and quality control. But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are spurring Chinese companies to request products from local rivals like Shanghai Titan Scientific and Nanjing Vazyme Biotech instead, the executives and managers said. The five who spoke to Reuters work at Chinese firms involved in the purchase or supply of reagents and their comments are an early sign of an expected industry shift toward more Chinese purchases. China's reagent market for lab and diagnostic use has been to some extent supplied by imports, which were valued at $5.76 billion in 2024, down slightly from $5.83 billion in 2023, according to U.N. Comtrade data. "It is actually more advantageous (for reagents to be local) because the timeliness requirement is high," said Ma Xingquan, co-president of pharmaceutical research firm ChemPartner PharmaTech. Most reagents it uses in its pre-clinical work are products that are made in China by firms including Titan and Shanghai Aladdin Biochemical Technology, he said. ChemPartner's usage of locally made reagents would probably increase further as new products become available, Ma added. TARIFF BUMP The rush to use domestically made reagents has accelerated since April, the month China raised duties on U.S. goods to 125%, a manager at Titan and an executive at Vazyme said, though the levies have since been lowered as Beijing and Washington continue trade talks. Some Chinese drugmakers were worried about tariff policy uncertainty, Titan product manager Yang Dong said. Since April, more than 90% of Vazyme's customers have discussed replacing imported reagents with its products, Vazyme Senior Vice President Xu Xiaoyu said. "Before April, customers were only saying long term, they hope to be able to replace (reagents) with those locally made, it would be better," Xu said. "But to customers these tariffs are like a shock in a short period of time. They clearly felt this type of direct impact... their impetus (for replacement) will be stronger." Titan and Vazyme are both forecast to report strong sales growth this year, according to brokers. China International Capital Corp expects Titan's annual revenue to grow 22% to 3.52 billion yuan ($490.39 million) this year, while Vazyme's revenue is set to rise 15% to 1.59 billion yuan over the same period, according to Soochow Securities. "There is still a lot of room for substitution of imported biological reagent enzymes, clients are strongly interested in locally-made replacements," Soochow said in a recent note. Shares in Titan and Vazyme have risen about 54% and 18% respectively since the start of the year. Merck and Thermo Fisher shares have fallen about 21% and 8% respectively over the same period. CHINA CHALLENGES Morningstar analyst Max Jousma expects China's reagents market to grow more than 10% annually over the next five years, driven by government support for the biotech and pharmaceutical sectors and growth in research and development activity and in-vitro diagnostic testing. Merck and Swiss diagnostics group Roche Holding are moving some of their reagent production closer to their Chinese customers. In 2023, Merck announced plans to invest 70 million euros ($81.35 million) in a reagents facility in Nantong that is on track to begin operations next year. Merck declined to comment on any short-term shifts in ordering patterns from Chinese customers. "The decision to invest in reagent manufacturing in Nantong reflects our commitment to supporting the growing needs of life science and biopharma customers in China and the broader Asia-Pacific region," it said in a statement. Roche is expanding production, laboratory and logistics facilities from 2028 in Suzhou, where it produces reagents for diagnostic systems, the company said in a statement. The expansion will help it meet increasing demand for diagnostic solutions in China and parts of Asia-Pacific, it said. Thermo Fisher declined to comment on its reagent sales and strategy to compete against local manufacturers in China, citing a policy of not providing details of its business by product line or country. Chinese drugmakers that use reagents from Western companies and are looking to purchase substitutes from local firms will face some challenges given the products are difficult to switch during or after the regulatory approval process because of a need for material consistency, industry experts said. "Switching reagents will cause significant disruption and delay for drug development," said Huang Linfeng, a scientist specialising in RNA biology at Duke Kunshan University. Another hurdle is manufacturer access to technology or processes, some of which could still be protected under patent or not disclosed, said Cheng Shaojun, a vice-general manager at supplier Fu Chen (Tianjin) Chemical Reagents Co. "(Reagent) production equipment is also not necessarily able to be bought," he added.

SHANGHAI, June 21, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Yinfei Yin, Ph.D. as vice president of and head of the biology and pharmacology department at Shanghai ChemPartner. Dr. Yin brings a wealth of experience and expertise to his new role, having established himself as a highly accomplished scientist in both academia and the biopharmaceutical industry. With a PhD in oncology from the University of Nottingham, Dr. Yin is a molecular biologist by training and possesses extensive experience in target discovery and validation, assay development, preclinical imaging, and advanced in vivo models. Prior to joining ChemPartner, Dr. Yin was the executive director and head of scientific operations (US/UK) and the global head of preclinical imaging at CrownBio for over 10 years. "Dr. Yin is an exceptional addition to our team, providing leadership and expertise to our biology and pharmacology efforts for drug discovery and development," said Lilly Xu, President of Shanghai ChemPartner. "His extensive research and leadership experience will greatly benefit ChemPartner and our global clients." As a leading, global CRO and CDMO, ChemPartner provides integrated life science services for drug discovery and development with expertise in discovery chemistry, biology, pharmacology, DMPK, exploratory toxicology, biologics discovery and development, and biologics manufacturing. ChemPartner's biology and pharmacology department specializes in drug discovery services for several key bio-therapeutic areas, including oncology, cell biology, immunology, inflammation, neuroscience, and metabolic disorders. From target validation, HTS, hit-to-lead, lead optimization, and candidate selection to IND-enabling studies, ChemPartner scientists are innovation-driven and customer-focused. Dr. Yin expressed his enthusiasm about joining ChemPartner and building upon the solid foundation established over the past two decades, stating, "ChemPartner is uniquely positioned as an integrated service provider with a strong track record of success. I believe the team's extensive discovery experience, combined with my expertise, will enable us to offer unmatched research solutions to our clients worldwide." About ChemPartner ChemPartner is the holding company of Shanghai ChemPartner and offers a broad range of drug discovery, development, and manufacturing services including discovery chemistry, biology, pharmacology, DMPK, and toxicology as well as biologics discovery, development, and manufacturing CDMO services. Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan. FOR MORE INFORMATION Livia Legg, MS, Chief Commercial Officer [email protected] SOURCE Shanghai ChemPartner